Konstantinos Katsanos

Dr
  • Country: GR

Activities

Comment on Jan 22, 2019

Gladiol Zenunaj commented on presentation VRTD 2: Association between PTX-coated devices and overall mortality.

»Greetings, thanks for sharing your research. The authors are reporting that mortality paclitaxel- related is dependent on the dose loaded on the device. Do the authors think that mortality paclitaxel-related after 1 year could depend whether on the paclitaxel load transferred to vessel wall or the load lost in the bloodstream during the delivering of the device. If this could be related to the load of paclitaxel lost during the delivering it shuld urge the developement of better drug bonding to the device.«
Comment on Jan 14, 2019

Gladiol Zenunaj replied to your comment on presentation VRTD 2: Association between PTX-coated devices and overall mortality.

»Very interesting paper. However, if their findings are confirmed in other studies, I think it might have any impact on the PTX-devices use rather than reducing the number of endovascular procedures. Nowadays, the increasing age, number of comorbidities of patients we have to deal with, make an open approach unthinkable.«
Comment on Jan 14, 2019

Konstantinos Katsanos commented on presentation VRTD 2: Association between PTX-coated devices and overall mortality.

»RCTs were included only in the meta-analysis. The paclitaxel arms and the control arms had similar-comparable baseline demographics without any significant differences (please refer to Appendix of the paper in JAHA). Not all studies had the same periods of follow-up time. Hence, the different number of studies for each time point. Our raw data is available 'open access' in the paper for any body to double-check. Independent reviews are of course more than welcome.«
Comment on Jan 13, 2019

Giovanni Torsello commented on presentation VRTD 2: Association between PTX-coated devices and overall mortality.

»I am not a statistician. But the statement "the two group are identical" is wrong. The groups may be comparable. Randomization was for sure not done for life expectancy, but for lesion characteristics. We need the opinion of a statistician. The study was not accepted for publication in "high ranked" Journals. Why? Additionally, the comparison of many studies at the beginning and of a few studies at 2 and 5 years looks "strange" in my opinion. The studies were externally controlled by Independent committees. What is the reason why they did not find safety issues? It is a pity that these points were not addressed during the round table.«